{"entity":{"id":"nct00143416","kind":"trial","name":"Long Term Study With B2036-PEG","aka":[],"tldr":"A phase 3 trial of Pegvisomant in Pituitary tumours, run by Pfizer, completed.","summary":"Long Term Study With B2036-PEG is a phase 3 interventional study registered as NCT00143416 by Pfizer, with 16 participants recorded, started 2004-04. Interventions recorded: Pegvisomant. Conditions recorded: Acromegaly.\n\nLinked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00143416","url":"https://clinicaltrials.gov/study/NCT00143416"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["pegvisomant"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00143416","phase":"3","setting":"Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -","sponsor":"Pfizer","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00143416/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}